2020 Pediatric Grand Rounds | Progress Towards Safe, Curative Treatment of Blood and Immune Diseases; Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation
Hematopoietic cell transplantation has been historically a niche field with treatments that are only provided to the sickest of patients that lack alternative treatments; however this is likely to change with the development of improved conditioning regimens, which is important to recognize and consider. Although hematopoietic cell treatments exist for many blood and immune diseases, not many patients or practitioners know about the best current treatments or their limitations. Moreover, many people do not know about the upcoming therapies that are in development, which are likely to become available for patients in the future.
Pediatric Hematology/Oncology/Stem Cell Transplant Physicians, Advance Practice Practitioners, staff and research team.
- Examine opportunities and current limitations of hematopoietic cell transplantation.
- Identify opportunities for non-genotoxic conditioning to improve hematopoietic cell transplantation.
- Discuss clinical non-genotoxic conditioning therapies in development at Stanford and elsewhere.
- Demonstrate opportunities for use of hematopoietic cell transplantation outside current practice areas.
Virtual Meeting- Zoom
Agnieszka Czechowicz, MD, PhD Assistant Professor of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine; Stanford University
Dr. Czechowicz has indicated that she receives Grant/Research Support from Rocket Pharmaceuticals; is a Consultant for Beam Therapeutics; is a Stock/Shareholder in Beam Therapeutics, Editas Medicines, and Magenta Therapeutics; has Other financial/material interests in GV management company.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2020 Pediatric Grand Rounds | Progress Towards Safe, Curative Treatment of Blood and Immune Diseases; Learnings from the Development of Novel Conditioning Regimens for Hematopoietic Cell Transplantation for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance